Sit Less, Interact and Move More (SLIMM) 2 Study
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: kidney
- Who it enrolls
- age 20 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Chronic Kidney Diseases; Obesity
- Interventions
- SLIMM; Standard Resistance Training; Guided Resistance Training; Placebo; Semaglutide
- Conditions
- Chronic Kidney Diseases; Obesity
- Phase and size
- Phase 2 · 156 participants
- Dates
- Start 2021-12-01
Primary completion 2026-12-31 - Sponsor
- Srinvasan Beddhu (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Average Change in Sedentary Duration at Months 8, 10 and 12 from RandomizationRandomization to 12 Months
02Eligibility
Who can take part
Inclusion Criteria: * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2 * Able to perform resistance training * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop Exclusion Criteria: * Type 1 Diabetes * History of gastroparesis or paralytic ileus * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. * Previous bariatric surgery * Medical condition likely to limit survival to less than 1 year * Anticipated start of dialysis or kidney transplantation within 6 months * Any factors judged by the investigator or study team to likely limit adherence to interventions * Vulnerable populations- pregnant or incarcerated * Enrolled in interventional trials using drugs or devices * Not able to undergo informed consent * Recent hospitalizations or major interventional procedures done within the past 60 days * Known or suspected hypersensitivity to tegaderm * Use of any GLP-1 receptor agonist within 30 days prior to screening * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system) * Presence of metastatic cancer * Current use of mobility aid(s) * Living in the same household of a participant already enrolled in the study
03Change log
Registry changes
No changes recorded since the trial was added.